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Introduction: Lung cancer (LC) is highly prevalent worldwide, with elevated mortality. In
this population, taste and smell alterations (TSAs) are frequent but overlooked symptoms.
The absence of effective therapeutic strategies and evidence-based guidelines constrain
TSAs’ early recognition, prevention and treatment (Tx), promoting cancer-related
malnutrition and jeopardizing survival outcomes and quality of life.
Objectives: To systematically review the literature on TSAs in LC patients, understand the
physiopathology, identify potential preventive and Tx strategies and to further encourage
research in this area.
Methods: Literature search on English language articles indexed to PubMed, CINALH,
SCOPUS and Web of Science using MeSH terms “Lung neoplasms”,”Dysgeusia”,
“Olfaction Disorders”, “Carcinoma, Small Cell”,”Carcinoma, Non- Small-Cell Lung
“Adenocarcinoma of Lung”,”Carcinoma, Large Cell”, and non-MeSH terms
“Parageusia”, “Altered Taste”, “Smell Disorder”, “Paraosmia”, “Dysosmia”,”Lung
Cancer” and “Oat Cell Carcinoma”.
Results: Thirty-four articles were reviewed. TSAs may follow the diagnosis of LC or
develop during cancer Tx. The estimated prevalence of self-reported dysgeusia is 35-38%
in treatment-naïve LC patients, and 35-69% in those undergoing Tx, based on studies
involving LC patients only. One prospective pilot trial and 1 RCT demonstrated a clinically
significant benefit in combining flavor enhancement, smell and taste training andNovember 2021 | Volume 11 | Article 7740811
Spencer et al. Dysgeusia and Dysosmia in Lung Cancer
Frontiers in Oncology | www.frontiersin.orgindividualized nutritional counselling; a systematic review, 1 RCT and 1 retrospective study
favored using intravenous or oral zinc-based solutions (150mg 2-3 times a day) for the
prevention and Tx of chemotherapy (CT) and radiotherapy (RT) -induced mucositis and
subsequent dysgeusia.
Conclusions: This is the first review on dysgeusia and dysosmia in LC patients to our
knowledge. We propose combining taste and smell training, personalized dietary
counselling and flavor enhancement with oral zinc-based solutions (150mg, 2-3 times a
day) during CT and/or RT in this population, in order to prevent and help ameliorate Tx-
induced dysgeusia and mucositis. However due to study heterogeneity, the results should
be interpreted with caution. Developing standardized TSA measurement tools and
performing prospective randomized controlled trials to evaluate their effect are warranted.Keywords: dysgeusia, dysosmia, taste and smell alterations (TSAs), lung cancer, dietary counselling, zinc,
weight lossINTRODUCTION
The second most frequently occurring cancer globally is lung
cancer, with an incidence of 2,206.77 (excluding non-melanoma
skin cancers), only surpassed by breast cancer. Also, it has the
highest mortality of any cancer, accounting for 1,796,144 deaths
in 2020 (1).
Whilst many symptoms are associated with lung cancer,
clinicians frequently observe taste and smell alterations (TSAs).
TSAs can be present upon initial diagnosis or develop during the
course of cancer treatment, and can lead to a change in food
preferences, resulting in reduced nutrient intake, a higher
probability of weight loss and impact on patient’s health-
related quality of life (HRQoL) through a decrease in the
pleasure of eating (2).
Although taste and smell belong to anatomically distinct
systems, they are intimately connected in the sensory
perception of food (3).
The chemical interplay between taste and smell senses is
critical in helping humans gather information about themselves
and their surrounding environment, from aiding social
interaction, detecting potential dangers and the enjoyment of
food consumption (4).
When consuming food or drinks, saliva helps dissolve tastant
molecules facilitating their interaction with taste receptors in the
mouth, leading to the activation of subsequent cascades that send
signals to the brain through specialized nerve cells. The signals
generated by the five basic tastes – bitter, salty, sour, sweet and
umami - interact with other signals triggered by eating and
drinking, such as smell and the trigeminal sensations of irritancy,
temperature and texture. Together, these combine to create the
sensations associated with flavor. Upon stimulation, taste bud
cells trigger the activation of proximal gustatory afferent fibers
that convey signals, via the facial (VII), glossopharyngeal (IX)
and vagal (X) nerves, to the rostral division of the solitary tract
nucleus in the brain stem. Additional taste neurons of a higher-
order project these signals to the thalamus and subsequently to2
the gustatory cortex. The taste signals are then projected to a
variety of brain structures via neurons in the gustatory cortex,
including the mid-brain dopaminergic regions, amygdala, and
orbitofrontal cortex. The orbitofrontal cortex is also targeted by
neurons involved in olfaction and oral mouth-feel which is
thought to be central in perceiving flavour (5).
The axons of olfactory sensory neurons project signals to the
olfactory bulb. The piriform cortex is the main recipient of
afferents from the olfactory bulb. The axons of neurons
projected from the olfactory bulb are broadly dispersed across
the surface of the piriform cortex, and individual piriform cortex
neurons respond to numerous, chemically distinct odorants,
clustering odor representations and enabling them to
preferentially signify odor relationships (6).
The olfactory and taste systems can be damaged in multiple
ways that reduce their function, including age, bacterial and viral
illnesses, trauma, surgical damage, severe allergies, chronic
rhinosinusitis, inborn genetic disorders, neurological diseases,
some medications and cancer treatments (4).
Both quantitative and qualitative changes can occur as a result
of taste disorders. Quantitative changes include ageusia (total
taste loss), hypogeusia (partial taste loss) and hypergeusia
(increased taste responsiveness). Qualitative changes include
phantogeusia (the sensation of taste with stimuli absent, also
known as “oral phantoms”) and dysgeusia (the persistence in the
mouth of slaty, bitter, rancid or metallic taste sensations after
finishing a meal (3, 5).
Typically, smell disorders are divided into four categories,
depending on their odor perception impact. Firstly, the absence
of smell perception, or Anosmia. Secondly, a quantitatively
reduced ability to perceive smells, or Hyposmia. Thirdly, a
qualitative distortion of the normally perceived smell, or
Parosmia. And finally, the perception of smells in the absence
of an odor, or Phantosmia (4).
TSAs can be evaluated through quantitative analysis,
chemical stimuli or surveys (6). As described above, the nature
of the chemical senses is incredibly complex and interconnected,November 2021 | Volume 11 | Article 774081
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However, a limiting factor to the evaluation of TSAs arises
from the heterogeneity of the systems used to measure them and
the fact that these symptoms are often underestimated and
overlooked, probably due to their non-life-threatening
nature (8).
Dysgeusia affects 46-77% of patients with cancer, from
roughly 53% of pat ients rece iv ing treatment with
chemotherapeutic drugs, to 66% of those receiving
radiotherapy (RT) and 76% of those patients prescribed both
treatments (2, 8–11).
One review reported a prevalence of 12-84% of self-reported
taste problems among cancer patients (12).
Another review of patients receiving chemotherapy (CT)
reported a prevalence of alterations to taste of 45-84% and of
alterations to smell of 5-60%. It also found that in patients with
advanced cancer, almost 80% reported TSAs (13).
One unicentric study involving 239 patients with different
cancer types undergoing cancer treatment (including nine
patients with lung cancer) reported a 54% rate of dysphagia,
62% rate of taste changes and 35% rate of smell changes (14).
These wide ranges relate to study heterogeneity and the
absence of standardized questionnaires and methodologies for
patients to self-report the presence of chemosensory alterations
(3, 12).
Malnutrition is a common finding in cancer patients, with an
incidence varying between 31–87%. Undernutrition and weight
loss may result from reduced energy intake, increased energy
requirements, impaired nutrient absorption, tumor-related
catabolism and inflammation leading to muscle wasting,
anticancer treatment side effects and patient ’s poor
psychological state (15).
A study by Joseph P.V. et al. performed with 1,329 cancer
patients of various types undergoing CT, concluded that patients
reporting treatment-related taste alterations suffered significantly
from neuropsychological symptoms. These included higher
levels of depression, anxiety, sleep disturbance and fatigue
when compared to patients with no change in taste (16).
In line with the psychosocial impact of CT, Sasaki et al.
evaluated the perception of symptoms through a 94-item
questionnaire in 49 patients receiving chemotherapy in a
hospital in Japan. It was concluded that the most frequent and
troublesome non-physical concern of patients was the fact that
“it affected their families or partner” (17).
Multiple studies have highlighted that poor prognosis and
quality of life (QoL) in cancer patients is intimately associated
with weight loss, which in turn raises the probability of adverse
side-effects from treatment and impairing the response of a
tumor to therapy (15).
This is reflected by the fact that malnutrition, and not
malignancy, is responsible for 20% of cancer patients deaths,
meaning it is essential for patients to maintain an appropriate
dietary intake throughout their cancer treatment (18).
This scoping review aims to comprehensively understand the
pathophysiology, impact, prevention, and treatment of TSAs in
lung cancer patients, and to identify gaps in our current scientificFrontiers in Oncology | www.frontiersin.org 3knowledge so as to encourage further research in those areas. A
preliminary search on Pubmed and the Cochrane Database of
Systematic Reviews was conducted and no existing or in progress
systematic reviews on this topic were identified.METHODS
Inclusion Criteria
This scoping review was built on the basis of “The Joanna Briggs
Institute”methodology. The inclusion criteria for this review were
based upon the PCC elements (Population, Concept and Context).
This review examined all studies and reports focusing on TSAs
occurring in adult lung cancer patients, either being treatment-
naïve or submitted to cancer treatment, even if the studies were not
limited to this specific cancer type. Studies focusing on the
pathophysiology, management and treatment approaches of
TSAs were also considered.Types of Sources
This scoping review considered experimental and quasi-
experimental study designs, including randomized controlled trials,
non-randomized controlled trials, before and after studies and
interrupted time-series studies. Analytical observational studies,
including prospective and retrospective cohort studies and
analytical cross-sectional studies; and descriptive observational
study designs including case series, individual case reports and
descriptive cross-sectional studies, were considered for inclusion.
Text and opinion papers that met the inclusion criteria were
also considered.Search Strategy
A literature search was performed in July 2021 including English
language papers indexed to Pubmed, CINALH, SCOPUS andWeb
of Science, using the MeSH terms “Dysgeusia”, “Olfaction
Disorders”, “Lung neoplasms”, “Carcinoma, Non-Small-Cell
Lung”, “Carcinoma, Small Cell”, “Adenocarcinoma of Lung”,
“Carcinoma, Large Cell”, and the additional search terms
“Altered Taste”; “Parageusia”, “Smell Disorder”, “Dysosmia”,
“Paraosmia”, “Lung Cancer” and “Oat Cell Carcinoma”, with no
date range filter (Table 1). Articles from other sources were also
searched to complement the review.Additionally, bibliography lists
of all retrieved articles were searched for relevant studies.Data Extraction and Presentation
Datawere extracted frompapersby twoauthors independently, using
the Rayyan data extraction tool. The data extracted included specific
details about TSAs in cancer patients in general and in lung cancer
patients, as well as key relevant information to the review questions.
Where there was disagreement between authors, the issues were
discussed to reach a consensus. Following extraction, all full texts
were subsequently independently screened by the reviewers. The
extracted data are presented in tabular form, to align with theNovember 2021 | Volume 11 | Article 774081
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accompany the tabulated results to describe the relationship between
the results and the review’s objective and questions.RESULTS
Study Inclusion
A total of 1,960 citations were identified. After duplicate removal
(n=159), 1,802 titles and abstracts meeting the inclusion criteria
remained for analysis. 1,752 references were then excluded, with
50 full texts retrieved for analysis. Sixteen studies were excluded,
leaving 34 articles to be included in this review. The PRISMA
flowchart (Figure 1) describes the flow of decisions of this
process. Table 5 records studies ineligible following the full
text review.Review findings
Factors Influencing TSAs
The exact underlying mechanisms behind chemosensory
alterations in cancer patients is not fully known, due to odor and
taste abnormalities having a multifactorial etiology, heterogeneous
cancer population studies, variability of the definition of “taste” and
on the endpoints used in the studies, as well as the lack of
standardized measurement tools to evaluate TSAs (3, 12).
A study by Belqaid et al. demonstrated that the intensity of
TSAs tends to change over time within the course of lung cancer
treatment. Additionally, TSAs are influenced by the presence of
additional symptoms, side-effects of treatment and other
individual and contextual factors (19).
Additional factors can also contribute to reduced smell and
taste perception, including, poor oral hygiene, lack of saliva and
alcohol or nicotine abuse (20).
Eating-related symptoms such as nausea, dry mouth,
premature satiety, appetite loss and fatigue also interrelate with
TSAs (21).Frontiers in Oncology | www.frontiersin.org 4Xerostomia is highly related to taste alteration, as food
particles stimulate taste bud taste receptor cells within the
lingual papillae, when in solution. Therefore, reduced secretion
and increased saliva viscosity may interfere with flavor molecules
being transported to taste and olfactory receptors (3).
In addition, changes in cell volume or osmolar content of any
of the central nervous system neurons implicated in the sense of
taste are influenced by extracellular hypo-osmolality and may
potentially inhibit the sense of taste (22).
In a systematic review by Nolden et al., the majority of the
reviewed articles identified no significant relationship between
measures of smell or taste and intake of food and enjoyment.
However, it was suggested that where lower taste sensitivity is
experienced by patients (higher detection thresholds), incidences
of food avoidance also increase. The most common taste
alterations were observed for sweet and, to some extent, bitter
perception, whereas alterations in cancer patients to salt and sour
perception where less frequent. The alterations were associated
with lower consumption, appetite, and patients avoiding certain
foods (12).
Williams and Cohen compared the taste threshold levels of 30
male lung cancer subjects before the start of RT or CT with a
healthy control group, demonstrating a significant reduction in
the sensitivity for sour in the lung cancer group. No significant
differences were noted concerning sweet, bitter or salty tastes,
although there were individuals with recognition levels that
differed considerably from controls. It was concluded that diet
therapy management for lung cancer patients should be
individualized, in order to maintain the diary amount of
protein and calories (23).
Turcott et al. evaluated changes in the thresholds for detecting
and recognizing sweet, bitter and umami tastes in patients with
non-small cell lung cancer (NSCLC) receiving CT treatments of
cisplatin and paclitaxel-based, as well as their association with
nutritional and HRQoL parameters. It was concluded that taste
buds’ impairment and disturbance of renewal cell processes
might increase the detection thresholds for sweet, sour, salty,
bitter or umami. On the other hand, higher sensitivity to umamiTABLE 1 | Summary of the search strategy.
Search Strategy
Pubmed [(((((((((((Taste Disorders[MeSH Terms)] OR Taste Disorders[Title/Abstract]) OR Dysgeusia[MeSH Terms]) OR Dysgeusia[Title/Abstract]) OR Olfaction Disorders
[MeSH Terms]) OR Olfaction Disorders[Title/Abstract]) OR Altered Taste[Title/Abstract]) OR Parageusia[Title/Abstract]) OR Smell Disorder[Title/Abstract]) OR
Dysosmia[Title/Abstract]) OR Paraosmia[Title/Abstract])) AND ((((((((((((Carcinoma, Large Cell[MeSH Terms]) OR Carcinoma, Large Cell[Title/Abstract]) OR
Adenocarcinoma of Lung[MeSH Terms]) OR Adenocarcinoma of Lung[Title/Abstract]) OR Carcinoma, Small Cell[MeSH Terms]) OR Carcinoma, Small Cell
[Title/Abstract]) OR Carcinoma, Non-Small-Cell Lung[MeSH Terms]) OR Carcinoma, Non-Small-Cell Lung[Title/Abstract]) OR Lung neoplasms[MeSH Terms])
OR Lung neoplasms[Title/Abstract]) OR Lung Cancer[Title/Abstract]) OR Oat Cell Carcinoma[Title/Abstract])
CINAHL (MM Lung neoplasms OR TI Lung neoplasms OR AB Lung neoplasms OR MM Carcinoma, non-small cell lung OR TI Carcinoma, non-small cell lung OR AB
Carcinoma, non-small cell lung OR MM Carcinoma, Small Cell OR TI Carcinoma, Small Cell OR AB Carcinoma, Small Cell OR MM Adenocarcinoma of Lung
OR TI Adenocarcinoma of Lung OR AB Adenocarcinoma of Lung OR TI Carcinoma, Large Cell OR AB Carcinoma, Large Cell OR TI Lung Cancer OR AB
Lung Cancer OR TI Oat Cell Carcinoma OR AB Oat Cell Carcinoma) AND (MM Dysgeusia OR TI Dysgeusia OR AB Dysgeusia OR MM Olfaction disorders
OR TI Olfaction disorders OR AB Olfaction disorders OR MM Taste Disorders OR TI Taste Disorders OR AB Taste Disorders OR TI Altered Taste OR AB
altered states of consciousness OR TI Parageusia OR AB Parageusia OR TI Smell Disorder OR AB Smell Disorder OR TI Dysosmia OR AB Dysosmia OR TI
Paraosmia OR AB Paraosmia)
Web Of
Science
Search similar to the two search engines above
SCOPUS Search similar to the two search engines aboveNovember 2021 | Volume 11 | Article 774081
Spencer et al. Dysgeusia and Dysosmia in Lung Cancerrecognition (hypergeusia) had significant association with a
global HRQoL status deterioration and loss of appetite
(p=0.016 and 0.115 respectively) (24).
McGreevy et al. investigated the characteristics of severe TSAs
reported by 89 lung cancer patients undergoing CT. Patients
reporting TSAs were younger and more frequently smokers.
Gender was a statistically significant variable, with higher
numbers of women reporting TSAs (25).
On the other hand, Yoshimoto et al. investigated CT impact
on the smell and taste of 35 Japanese patients with lung cancer
through the use of questionnaires, identifying no statistically
significant associations between smell alterations and age, gender
or smoking history. Patients became more sensitive to sweet and
salty tastes, but less so for umami and bitter. This might haveFrontiers in Oncology | www.frontiersin.org 5been influenced by patients’ psychological stress, oral hygiene
and smoking status, as well as the study’s small sample size (11).
Amézaga et al. also found no statistically significant differences in
taste and smell alterations between older and younger patients (3).
Zabernigg et al. found that elderly patients or patients with
nicotine abuse reported fewer TAs, which might be explained by
the fact that these two groups already tend to suffer from
hypogeusia of some degree, making CT-induced changes less
noticeable (10).
Taste and Smell Alterations in Treatment- Naïve
Lung Cancer Patients
Table 2 summarizes the existing evidence on TSAs in treatment-
naïve lung cancer patients, included in the review. Turcott et al.FIGURE 1 | PRISMA flowchart outlining the process for selecting the included articles.November 2021 | Volume 11 | Article 774081
Spencer et al. Dysgeusia and Dysosmia in Lung Cancerfound a 35% prevalence of self-reported dysgeusia among 65
treatment-naïve non-small cell lung cancer patients submitted to
self-reporting taste and smell questionnaires and a rinse stimuli
technique. A minimal concentration of taste stimuli was required
for most patients to perceive the stimuli; however they commonly
could not recognize the taste. Patients with dysgeusia presented
with a significantly reduced lean-bodymass (p=0.027), a significant
increase in fat mass (p=0.027) and gastrointestinal symptoms,
including nausea (p=0.042), anorexia (p=0.004), early satiety
(p<0.0001) and reduced food consumption (p=0.01). They also
had clinically significant alterations in HRQoL scales (2).Frontiers in Oncology | www.frontiersin.org 6In another study, Turcott et al. found self-reported dysgeusia
was prevalent in 37.5% of NSCLC treatment-naïve patients, and
a 34.5% prevalence post-CT, revealing a drastically high rate of
taste disorders prior to CT, comparing to that of the general
population (0.07-1.7%) - meaning that dysgeusia could be caused
by the disease itself (24).
An observational study by Belqaid et al. involving 215
patients under investigation for lung cancer, found a self-
reported TSA prevalence of 38% in the group of patients
diagnosed with lung cancer (n=117), and symptoms were in
general mild (13).TABLE 2 | Summary of evidence concerning treatment-naïve lung cancer patients included in the review.
























-35% prevalence of self-reported dysgeusia
-Pts with dysgeusia had less lean body mass (p=0.027); higher fat
mass (p=0.027); nausea (p=0.042); anorexia (p=0.004); early satiety
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-38% prevalence of TSAs in pts with and without lung cancer;
generally mild







N=60; 30 male pts with






-Lung cancer pts had lower sensitivity for sour (p=0.05)
Singh et al.
(30)
2009 Case Report – – – - Case report of concomitant dysgeusia, hyponatremia and SCLC.
- Dysgeusia is rarely seen with SIAD; various reports on its
association with lung cancer, mostly with SCLC histology.
Nakazato
et al. (27)
2006 Case Report – – – - Case report of dysgeusia (sweet taste of nearly all food) and
hyponatremia related to SIAD, found to be associated with large-cell
lung carcinoma.
-Dysgeusia might have been caused by the tumor producing an
unknown taste modifying substance, leading to structural changes in
the taste receptor membrane when the extracellular sodium levels
decreased. Miraculin could be a potential candidate substance.
Karthik et
al. (29)




2003 Case Report – – – -Case report of dysgeusia (constant sweet taste sensation) and
hyponatremia, found to be associated with a diagnosis of SCLC.
Ishimaru et
al. (26)
1999 Case Report – – – -Case report of a lung cancer metastasized to the right frontal lobe,
causing compression of the olfactory sulcus. The average olfaction






– – – -Changes in the extracellular sodium concentration may modulate the
sweet receptor.
- The onset of persistent dysgeusia (especially if unpleasant sweet
taste) should prompt measurement of serum sodium concentration
and the consideration of lung carcinoma.
Kamoi et
al. (39)
1987 Case Report – – – - Case report of SCLC associated with hyponatremia, renal sodium
loss and inappropriate antidiuresis, due to increased secretion of atrial
natriuretic peptide (ANP) by the atrial tissue. The natriuretic activity led
to the glomerular filtration rate increasing and a decrease in tubular
sodium resorption, increasing the renal fractional excretion of sodium.Pts, patients; SIAD, Syndrome of Inappropriate Antidiuresis; SCLC, Small Cell Lung Cancer; TSAs, Taste and Smell Alterations.November 2021 | Volume 11 | Article 774081
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after removal of a right frontal lobe lung cancer metastasis which
was causing slight compression and swelling of the olfactory area
in the brain (26).
Also, a triad of taste distortion with prominent sweet taste,
hyponatremia and lung cancer diagnosis was firstly reported in a
case series by Panayiotou et al., in 1995 (22).
Since then, few other reports have described the diagnosis of
lung cancer in the context of dysgeusia with unpleasant sweet
taste, with concomitant hyponatremia as the sole biochemical
anomaly (27–30).
It is necessary to consider the lung cancer induced syndrome
of inappropriate antidiuresis (SIAD) when cryptogenic dysgeusia
is identified, particularly if patients report an unpleasant sweet
taste (27).
For SIAD to be diagnosed, the osmolality of the patient’s urine
when the effective plasma osmolality is lowmust exceed 100mOsm
per kilogram of water. Additionally, it is essential for clinical
euvolemia to be present. Eliminating the underlying cause is the
only definitive treatment for SIAD. For the majority of SIAD cases
caused by malignant disease, effective antineoplastic treatment is
typically the best course of action (31).
The most frequently implicated histological type is the small
cell lung carcinoma. In all cases, dysgeusia seemed to disappear
rapidly with normalization of serum sodium concentration
(27–30).
One explanation for this is that extracellular sodium levels
may modulate sweet receptors. Hyponatremia may decrease
lingual sweetness receptor thresholds, although the sole cause
of taste alteration cannot be completely attributed to a low
sodium level alone. Nakazato et al. hypothesized that an
unknown taste modifying substance could be produced by the
tumor causing all foods to be interpreted by patients as sweet.
This might occur due to structural changes in the taste receptor
membrane when extracellular sodium levels decreased, allowing
attachment of the taste modifier to sites on the sweet receptor
(27). A candidate substance could be miraculin, a glycoprotein
extracted from the West African berries Richadella dulcifera,
which modifies taste through the alteration of taste receptor
configuration (27, 30).
Taste and Smell Alterations in Lung Cancer Patients
Undergoing Treatment
Multiple factors contribute to the risk of CT leading to toxic
effects in the oral cavity, including the high renewal rates of oral
tissues, damage to the mucosal microflora, salivary glands and
development of neuropathy, where axonal degeneration of nerve
conduction velocity occurs in up to 80% of cases affecting taste
sensitivity and contributing to dysgeusia. The glossopharyngeal,
facial and vagus nerves give rise to the corda tympani and greater
petrosal nerves, all involved in the taste pathway (24).
Table 3 summarizes the evidence on TSAs in lung cancer
patients undergoing systemic treatment, included in the review.
A study by Zabernigg et al. investigated the prevalence of taste
alterations (TAs) in 197 cancer patients undergoing CT, of which
54.3% had lung cancer. Almost 70% of patients reported TAs atFrontiers in Oncology | www.frontiersin.org 7least once during the study period, with 17.6% reporting
moderate to severe TAs (10).
CT for lung cancer may involve a platinum-based compound
and a third–generation agent, such as paclitaxel. Approximately
two thirds of patients reported some type of dysgeusia when
treated with paclitaxel-based CT (24).
In a study by Amézaga et al., CT with docetaxel led to the highest
taste alteration scores in patient self-assessments (3). Steinbach et al.
in Amézaga et al. foundCT based on taxanes resulted inmore severe
taste disorders, particularly for the salt tastant. Metallic tastes, bad
tastes in mouth and xerostomia have been reported in higher
frequencies with paclitaxel, vinorelbine, anthracyclines and
carboplatin. However, conclusions are limited by the use of a non-
validated questionnaire to measure TAs. The exact mechanism
causing metallic taste in patients receiving CT is unknown, but it
can be generated from the CT substances being secreted in saliva and
thus coming into contact with taste receptors (3).
Joussain et al. evaluated the olfactory performance of 15 lung
cancer patients receiving cisplatin-basedCT, concluding thatwhilst
cisplatin did not influence odor identification and detection, a
reduction in the pleasantness of food odors was evident,
impairing food-related hedonic pleasure and ultimately, QoL (32).
Minakata et al. reported a case of severe gustatory disorder
following the administration of a combination of cisplatin and
etoposide CT (33). It had previously been reported by Henkin et
al. in Minakata et al. (33) that cisplatin can displace zinc from its
normal binding site and induce the inactivation of gustin, with
consequent hypogeusia. Kanda et al. in Minakata et al. (33)
hypothesized that cisplatin-induced gustatory disorder could be
caused by disturbance to a receptor or a peripheral nerve.
Cisplatin and/or etoposide could suppress gustatory receptor
function, as well as leading to the occurrence of some
dysfunction of the central nervous system (33).
Radiotherapy aims to destroy cancer cells by directly breaking
the DNA helix strands, leading to cell death. Radiation to the
chest affects the significantly radiosensitive epithelial cells lining
the esophagus and pharynx. This can lead to radiation-induced
side effects that can affect swallowing by disruption of the normal
mucosal barrier and predisposition to fungal infection. Although
typically resolving within 2 weeks after treatment conclusion,
esophagitis and self-reported taste changes can continue to affect
patients for weeks to months (34).
As the epidermal growth factor receptor (EGFR) is
fundamental to epidermal and epithelial cells homeostasis,
cutaneous or mucosal toxicities are commonly associated with
the majority of anti-EGFR-treated patients (35).
Anap las t i c lymphoma kinase (ALK) and ROS1
rearrangements also represent an established molecular
alterations in a small subset of NSCLC (36).
Oral events induced by anti-EGFR TKIs are underreported
compared to skin toxicities. Monotherapy with Erlotinib leads to
an incidence of mucositis in patients of 8-20%, ranging between
17-24% with Gefitinib (35).
Crizotinib is a small-molecule, orally available tyrosine kinase
inhibitor, that can suppress the activity of ALK and oncogene
ROS1 kinases, causing cell cycle arrest at G1/S phase (37).November 2021 | Volume 11 | Article 774081
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11 studies including 578
participants (380 with
cancer and 198 controls);
all of the studies
evaluated taste change
and 5 also evaluated
smell changes
- Taste changes (detection and
recognition thresholds) for
sweet, sour, bitter, salty and
umami, and their relationship
between food behavior in
patients undergoing cancer
treatment.
- Smell changes (identification,
sensitivity and discrimination)
and their relationship between









- Cancer patients with appetite loss were more likely
to prefer reduced sweetness levels; compared with
patients without a reduced appetite. Effect sizes
showed that sweet taste had the highest empirical
evidence for food behavior involvement, with
reduced appetite and overall lower energy intake.
- The authors did not report any significant













- No significant associations between change in the
sense of taste and CT cycles, age or BMI, were
found. There was a trend towards an association
with current smoking (p=0.083).
- Patients reported a higher sensitivity to salty and
sweet tastes and a lower sensitivity to umami after
the start of CT.
- No significant associations between change in the
sense of smell and age, gender or smoking history
were found.
- Despite less favorable taste, Japanese patients did







patients; 13 women, 4
men





- TSAs implied coming to terms with the presence of
these symptoms and finding new personal strategies
to overcome them.
- Health-care professionals’ involvement was
generally described as limited. More normalizing
information, emotional support and practical advice














- Prevalence of 76% of taste disorders and 45% of
smell alterations.
- Anthracyclines, paclitaxel, docetaxel and
carboplatin produced highest taste disturbance rates
of all CT agents.
- Xerostomia was the most frequent symptom
reported, strongly associated with bad taste in
mouth and taste loss.







N=138 patients; n= 42
with cancer (2.4% lung










- Cancer patients had significantly increased
detection thresholds for tastants sweet (p=0.024),
salty (p=0.031) and umami (p=0.007) compared to
healthy individuals; and for sweet (p=0.004) and sour
(p=0.039), compared to patients with inflammatory
disease.
- No significant differences were found between




2017 Review – -Oral toxicities induced by
targeted therapies and
immune checkpoint inhibitors
– - The incidence of mucositis was found to be
between 8-20% with Erlotinib and between 17 to
24% with Gefitinib.
- Crizotinib has been associated with moderate
dysgeusia (grade 1-2) in 11-26% of treated patients.
- The incidence of moderate dysgeusia (grade 1 or
(Continued)Frontiers in Oncology | www.frontiersin.org 8 November 2021 | Volume 11 | Article 774081
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2) with immune checkpoint inhibitors has been
documented in 3% of PD-1 and PD-L1 treated
patients. Xerostomia (generally grade 1-2) has been
reported in about 6% of patients treated with













- Prevalence of dysgeusia during or after CT of 64%.
- There was a statistically significant correlation
between type of cancer and dysgeusia (p=0.012).
- There was a statistically significant correlation
between type of CT and occurrence of dysgeusia
(p=0.031).














- Prevalence of self-reported dysgeusia in treatment-
naive lung cancer patients 37.5%; post-CT 34.5%.
- CT induced a tendency for an increase in taste
acuity for umami (p=0.109) and sweet (p=0.092),












- TSA characteristics changed over time, relative to
the start of localized or systemic treatment. Patients’
experiences must be taken into account in order to










N= 89 patients under





- 69% prevalence of TSAs after the start of cancer
treatment
-Patients reporting TSAs were on average more
frequently smokers and younger
-Women reported stronger TSAs
-Patients with TSAs suffered more from loss of






15 patients with lung
cancer; 15 controls
- Olfactory performance - ETOC - Cisplatin CT in lung cancer patients impaired the
pleasure of perceived food odors (p<0.03), but not





N= 197 cancer patients









- 69.9% of patients reported TAs in at least at one
assessment time; 14.6% reported TAs in all
assessment times.
- 17.6% of patients reported moderate to severe
TSAs.
- TAs decreased significantly with age (p<0.001);
- Patients with nicotine abuse reported less TAs
(p=0.002)
- Gender was not significantly associated with TAs.
- TAs were significantly associated with appetite






N = 2793 patients
considered eligible from
14 studies
- Adverse Events - CTCAE
v4.0
- Systematic review reporting a rate of dysgeusia
with Crizotinib and Alectinib ranging between 11-
52%.
- The most common AEs observed with ALK
inhibitors were gastrointestinal toxicities.
- There were differences between the toxicity
patterns, with increased hepatic and gastrointestinal
toxicities with Ceritinib, Crizotinib leading to more
visual disorders, both Crizotinib and Alectinib
(Continued)Frontiers in Oncology | www.frontiersin.org 9 November 2021 | Volume 11 | Article 774081
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Japan, the incidence rate of dysgeusia was 16.8% (36).
A systematic review on ALK inhibitor studies, including
Crizotinib and Alectinib, reported a rate of dysgeusia ranging
between 11-52%. Despite none of them reporting high-grade
dysgeusia, this might be a cause of patient uncompliance (37).
Qian et al. in Koizumi et al. (38) conducted a meta-analysis of
Crizotinib published clinical trials and reported that the
Crizotinib doses must be lowered or discontinued in 6.5% of
patients due to toxicity. Koizumi et al. reported a case of G3 taste
alteration and loss of appetite after 5 days of treatment with
Crizotinib 250mg (twice daily), leading to a discontinuation of
the drug. Toxicity completely regressed after switching to
Alectinib 300mg (twice daily). It remains unclear whetherFrontiers in Oncology | www.frontiersin.org 10dysgeusia could be dependent on the dose of Crizotinib.
Whereas Crizotinib is a multi-target receptor TKI for ALK,
MET and ROS1, Alectinib is highly selective for ALK without
activity against MET and ROS1. It also remains unclear whether
MET and ROS1 signals could be involved in oral tissues or cells
impairment (38).
Moderate dysgeusia (grade 1 or 2) has been noted in fewer
than 3% of PD-1 and PD-L1-treated patients (35).
Management and Treatment of Taste and
Smell Alterations
Due to the increased risk of TSAs in lung cancer patients coupled
with the related risks of experiencing weight loss and
malnutrition, there is a high medical need for clinical trialsTABLE 3 | Continued





causing more dysgeusia and Brigatinib causing more
respiratory complications.
-Low grade AEs were most commonly observed,













N = 2028 Japanese
patients with ALK fusion
gene-positive NSCLC
treated with Crizotinib
- Adverse Events - CTCAE
v4.0
- Reported incidence rate of dysgeusia of 16.8%.
Koizumi et
al. (38)
2015 Case report – – – - Case report on Grade 3 dysgeusia and anorexia,
developing 5 days after starting treatment with
Crizotinib. Toxicity completely regressed after
switching to Alectinib.
- Crizotinib is a multi-target receptor TKI for ALK,
ROS1 and MET whereas, conversely, Alectinib
targets ALK very selectively without activity against
ROS1 and MET.
-It remains unclear whether MET and ROS1 signals
could be involved in oral tissues or cell impairment.
Minakata
et al. (33)
2002 Case report – – – - Case report of severe gustatory disorder following
the administration of cisplatin and etoposide CT
combination.
- It had been previously reported that cisplatin could
lead to zinc displacement from its typical binding
site, with gustin inactivation and subsequent
hypogeusia.
- Cisplatin-induced gustatory disorder could also be
caused by disturbance to a peripheral nerve or
receptor. The function of gustatory receptors could
be suppressed either by cisplatin and/or etoposide.
Some central nervous system dysfunction may also
occur.
- Gustatory disorders induced by anticancer agents
usually reduce patients quality of life.AEs. Adverse Events; CiTAS. Chemotherapy-induced Taste Alteration Scale; CT. Chemotherapy; CTCAE. Common Terminology Criteria for Adverse Events; EORTC QLQ-C30. European
Organization for Research and Treatment of Cancer; ETOC. European Test of Olfatory Capabilities; HRQL. Health Related Quality of Life; NSCLC. Non-Small Cell Lung Cancer; RECIST.
Response Evaluation Criteria in Solid Tumors; TAs. Taste Alterations; TSAs. Taste and Smell Alterations.November 2021 | Volume 11 | Article 774081
Spencer et al. Dysgeusia and Dysosmia in Lung CancerTABLE 4 | Summary of interventions to prevent or treat dysgeusia in cancer patients undergoing systemic treatment included in the review.



















- TSAs implied coming to terms with the presence of these
symptoms and finding new personal strategies to overcome
them
- Health-care professionals’ involvement was generally
described as limited; clinicians should be supported in providing
more practical advice, normalizing information, and emotional
support to better support patients manage TSAs.




2019 Phase II pilot
trial,
unicentric
























- After 12 weeks, a clinically significant improvement of >2
points in the taste score were observed in 92% (n=23) of the
intervention group patients, meeting the study’s primary
endpoint.
- Median QoL score did not significantly change in the
intervention group at week 12 (p= 0.811), although a relevant





































- In the experimental group, MNA scores and physical function





























- Zinc supplementation revealed the occurrence, onset or
severity of oral mucositis due to CT were not significantly
affected by the intake of zinc; although positive effects on oral
pain and severity and frequency of xerostomia were found.
- For patients receiving RT or radio-chemotherapy, zinc had a
significant impact on the onset, severity and duration of oral
mucositis (except in nasopharyngeal carcinoma patients).
- There was a common trend to taste improvement during
radiotherapy, but not chemotherapy.














- CTCAE v 4.0 - In patients who received oral Polaprezinc, the grade 2
dysgeusia’s 90 day recovery rates post symptom onset was
60%, significantly higher compared to the follow-up observation
group (p=0.0007).
- Grade 2 dysgeusia median recovery time was significantly
lower in the Polaprezinc group than in patients in the follow-up
(Continued)Frontiers in Oncology | www.frontiersin.org 11 November 2021 | Volume 11 | Article 774081
Spencer et al. Dysgeusia and Dysosmia in Lung Cancerfocused on novel interventions to improve taste and smell. No
guidelines for the treatment of smell and taste disorders are
available, with general nutritional counselling that is offered to
patients not earnestly addressing this subject (20). Table 4
provides the summary of interventions to prevent or treat
TSAs in lung cancer patients, included in the review.
Nutritional Counselling
To ensure appropriate nutritional counselling, information related
to possible taste changes that patients could experience should be
made clear before starting treatment. This necessitates providingFrontiers in Oncology | www.frontiersin.org 12clinicians with evaluation measures that have been validated and
ensuring they receive appropriate training in their use (12).
Belquaid et al. performed a qualitative interview to 17 lung
cancer patients in order to understand what strategies or
resources were used to deal with cancer-related TSAs. It was
concluded that limited support from health-care professionals
was provided, and that the majority of patients initiated
management strategies by themselves, including coming to
terms with TSAs, modifying their taste and smell experiences
and finding emotional support in family and friends. As part of
treatment, normalizing information about TSAs seemed to beTABLE 4 | Continued













- Polaprezinc was not as effective in elderly patients (≥65 years).
- Pancreatic cancer patients were less responsive to
Polaprezinc.
- The patients with the highest Polaprezinc response were those
suffering with colorectal cancer.
Doi et al.
(43)
2018 Review -Cites 4 RCTs on the











et al. involving 10
lung cancer patients
from a sample of 41
patients with multiple
cancer types)
-Taste Alterations - Quantitative and
qualitative
methods
- Yamagata et al. explored the intravenous infusion of zinc
during chemotherapy as a strategy for preventing taste
disorders in patients receiving CT for lung cancer, with
successful results.
- Lyckholm et al. reported the failure of using oral zinc sulfate at
220 mg twice a day in improving CT-related taste alteration,
loss or distortion of taste and smell, compared with placebo.
- The studies demonstrated varied administration routes and
dosing of zinc and Polaprezinc and included subjective forms of
assessment of dysgeusia. Further studies with large samples
using objective measures on taste testing should be conducted






N= 12 lung cancer
patients under CT




- Group B (n=5): CT
+ intravenous drip
infusion without zinc




- After 2 weeks of treatment, taste thresholds in all group B
patients worsened at the corda tympani nerve area, whereas
two thirds of patients in group A showed an improvement.
Electrical taste thresholds significantly differed between both
groups, after 2 and 4 weeks (p<0.05).
- Although not significant, patients in group A revealed an
improvement on the electrical taste thresholds in the
glossopharyngeal nerve area, at 2 weeks. At 4 weeks, there
wasn’t a significant difference in the taste characteristics in the






















- Amifostine significantly reduced the rate of mild, moderate and
severe esophageal toxicity (p=0.021), as well as the rate of
severe pneumonitis (p=0.020) and neutropenic fever (p=0.046).
- Mild hypotension (p<0.001), sneezing (p=0.039) and
dysgeusia (p=0.029) were significantly more frequent in the
Amifostine arm.
- Amifostine had no apparent effect on survival.CT, Chemotherapy; CTCAE, Common Terminology Criteria for Adverse Events; EORTC QLQ-C30, European Organization for Research and Treatment of Cancer; HRQL, Health Related
Quality of Life; MNA, Mini Nutritional Assessment; NCI, National Cancer Institute; NSCLC, Non-Small Cell Lung Cancer; PZ, Polaprezinc; Pts, patients; QoL, Quality of Life; RECIST,
Response Evaluation Criteria in Solid Tumours; TSAs, Taste and Smell Alterations; RT, Radiotherapy.November 2021 | Volume 11 | Article 774081
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reality, empowering patients to find their own solutions (21).
Maintaining protein intake is important for patients during
treatment. Therefore, adding high protein foods into a patient’s diet
should be encouraged, including eggs, dairy products, peanut
butter, mild-tasting fish, chicken and soy meat substitutes (34).
Additionally, patients suffering from ageusia can try other
techniques, such as flavoring meat, fish or chicken through sweet
juice marination, sweet wine, and other sources including sweet-
and-sour and Italian dressing. If nutritional supplements are too
sweet, patients can try other options, including unflavored
supplements or supplements that are based on juice or yogurt.
CT-related metallic taste can be overcome by using plastic
utensils, instead of metal ones (34).
For elderly patients or those suffering from umami
hypogeusia, umami savoriness could help reduce any
additional salt, sugar and fat consumption (24).
Taste and Smell Training
A clinical prospective pilot trial (the “TASTE trial”) assessed the
possible short-term impacts of training taste and smell by applying
the “Taste Strips Test” plus individual nutritional counseling to a
group of cancer patients undergoing chemotherapy (<= or “CT”),
3% (n=2) having lung cancer. After 12 weeks, the study’s endpoint
wasmet when a clinically significant improvement of >2 points was
observed in 92% (n=23) of the intervention group patients (20).
A study by Schiffman et al. enrolled 107 cancer patients above
55 years old, the majority with lung cancer, to an experimental arm
of flavor enhancement with aromas of actual foods plus nutritional
counseling (n=54) and compared it with a control arm receiving
nutritional information only (n=53). It was concluded that flavor
enhancement plus nutritional counseling could improve patients’
nutritional status and QoL, suggesting that it is possible to
minimize some chemosensory losses by providing cancer patients
with the knowledge to improve the flavor of their foods (41).
Zinc Supplementation
Despite multiple investigations into how zinc can impact cancer
treatment toxicities, there remains a lack of evidence to form a
common consensus on its role (42).Frontiers in Oncology | www.frontiersin.org 13To synthesize gustin, a salivary protein that is important in
ensuring the integrity of taste buds, sufficient levels of zinc are
required. Zinc deficiencies, therefore, can cause impaired taste
and odor sensitivity. Maeda et al. in Cranganu et al. (34)
investigated the impact of taste alterations in 36 advanced lung
cancer patients, and found higher taste abnormalities in patients
with reduced serum zinc levels compared with the normal zinc
level patient group (34).
A systemic review was performed by Hoppe et al. to evaluate
the role of systemic zinc supplementation as complementary
treatment for cancer patients (including 16 patients with lung
cancer). Zinc was found to have no significant effects on
chemotherapy-related oral mucositis or dysgeusia, although it
seems to have positive effects on the prevention, severity and
duration of RT or CT-induced oral xerostomia, mucositis and
dysgeusia (42).
Polaprezinc is a chelating compound and anti-ulcer drug
composed of a zinc ion, L-histidine, L-carnosine, and a b-alanine
dipeptide. It has been observed to have antioxidant properties
and to scavenge free radicals. Several preclinical and clinical
studies showed its efficacy in reducing radiation-induced normal
tissue damage. One review concluded that systemic Polaprezinc
may be an acceptable option for reducing toxicities from
chemoradiotherapy, being highly promising for preventing
normal tissue damage in this context (43).
Yamagata et al. suggested that administering zinc intravenously
during CT for lung cancer could help in preventing taste disorders
and aiding patients inmaintaining their QoL. Interestingly, a direct
correlation between taste sensation and plasma zinc concentration
could not be established, and the administration of zinc did not
parallel an increase in the plasma zinc concentration (44).
A single-center retrospective study evaluated how zinc affects
cancer patients’ taste disorders in which subjects with different
types of cancer (including 47 patients with lung cancer) suffering
from grade 2 CT-related taste disorders were given 150mg of zinc
twice daily orally until symptoms disappeared, vs a placebo
comparison group. The median recovery time was significantly
lower in the group where patients received zinc (63 vs 112 days;
p=0.019) (45).TABLE 5 | Summary of the excluded articles with reasons.
References Year Study type Reasons for exclusion
Gift et al. 2003 Retrospective, secondary analysis Background article
Turcott et al. 2018 Abstract poster Full article included in this review
Lederhandler et al. 2018 Case report Wrong outcome (refers specifically to oral mucositis)
Paule J.V. et al. 2020 Prospective, longitudinal Background article
Catania et al. 2020 Short Communication Wrong outcome (refers specifically to dysgeusia and anosmia related to SARS-COV2 infection)
Frowen J. et al. 2020 Cross-sectional study Background article
Simeone et al. 2019 Review article Background article
Van der Werf et al. 2018 Pilot Study Small sample and not exclusively related to lung cancer
Sasaki et al. 2017 Prospective study Wrong outcome (non-physical concerns) and not exclusively related to lung cancer
Wagland et al. 2016 Cross sectional Background article
Thorne et al. 2015 Review article Background article
Boltong et al. 2012 Systematic review Background article
Watters et al. 2011 Review Background article
Vadhan-Raj et al. 2010 Randomized Controlled Trial Wrong outcome (refers specifically to oral mucositis)
Sanchez-Lara et al. 2010 Cross-sectional study Background article
Ishinaga et al. 2018 Cross-sectional study Small sample and very specific to Japanese populationNovember 2021 | Volume 11 | Article 774081
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Amifostine is a potent exogenous, free-radical scavenger and an
established radioprotectant particularly for the prevention of
radiation-induced xerostomia (43). It is currently the only US
Food and Drug Administration (FDA) treatment for preventing
moderate to severe radiation-induced xerostomia. Additionally,
for patients with NSCLC or advanced ovarian cancer receiving
repeated doses of cisplatin, it reduces the cumulative renal
toxicity associated with treatment. Investigators have been
interested in using this drug to prevent or reduce the severity
of mucositis, but its effectiveness remains controversial (46).
One study examined the impact of amifostine on NSCLC
patients receiving concurrent CT and RT and whether it
impacted the acute toxicity associated with treatment.
Interestingly, it demonstrated that in patients given amifostine,
dysgeusia was more commonly present than in the control group
patients (47).DISCUSSION
From examining the literature, we believe no other reviews of
dysgeusia and dysosmia in lung cancer patients have been
conducted. TSAs are common in this particular population
and may follow the diagnosis of the malignancy or develop
during the course of cancer treatment, leading to a decrease in
nutrient intake, weight loss, poor health-related quality of life
(HRQoL) and worse disease prognosis.
TSAs’ intensity tends to change over time throughout the
course of lung cancer treatment. Individual and contextual
factors influence TSAs, including the presence of additional
symptoms, side-effects of treatment and the overall life-
situation of the patient (19).
Typically upon lung cancer diagnosis, a range of symptoms
are present and can remain for the duration of the disease. These
include weakness, fatigue, appetite and weight loss, nausea,
vomiting and taste alterations (48).
On this basis, detection of these symptoms should warrant
prompt assessment of chemosensory alterations (18).
In addition, it appears that the most predictive signal for the
number of symptoms clustering in a patient is the stage of cancer
the patient is experiencing (48).
Qualitative reports on TSAs changes are quite miscellaneous.
The underlying mechanism for chemosensory alterations in
cancer patients is not completely understood. This results from
cancer population study heterogeneity, the multifactorial nature
of odor and taste abnormalities, as well as the lack of
standardized measurement tools for TSAs (3).
Taste disturbances seem to be present not only in cancer
patients, but also, in patients suffering from inflammatory
disorders, suggesting that taste perception deterioration can be
linked to systemic inflammation inducing changes in interferon,
toll-like receptor pathway and lipopolysaccharide, reducing taste
progenitor cell proliferation and shortening taste bud cell
lifespan (40).Frontiers in Oncology | www.frontiersin.org 14For neoplastic disease, inflammation processes are induced by
the release of multiple pro-inflammatory cytokines, which could
be linked to the onset of taste disturbances. In this context, lung
cancer may lead to changes in cell volume or osmolar content in
central nervous system neurons, altering the sense of taste (22).
Upon observation of cryptogenic dysgeusia in lung cancer
patients, it is necessary to consider the syndrome of
inappropriate antidiuresis (SIAD), particularly if patients
report unpleasantly sweet taste (27).
Interestingly, Kamoi et al. reported a case of a small cell lung
cancer associated with hyponatremia, renal sodium loss and
inappropriate antidiuresis unrelated to abnormal ADH plasma
levels produced by the tumor. In this case, they were associated
with an increased secretion of atrial natriuretic peptide (ANP) by
the atrial tissue, resulting in a glomerular filtration rate increase
and a decrease in tubular resorption of sodium (39).
TSAs may also develop as a consequence of CT, TKIs or RT-
related side effects, through salivary gland damage and
neuropathy, alteration of the structure of taste pores or
conditioned aversions. A common complication of cytotoxic
RT and/or CT is oral mucositis, being associated with
dysgeusia, severe pain, odynophagia, malnutrition and
dehydration. Contributing factors to smell and taste perception
reductions include insufficient oral hygiene, xerostomia, older
age, and alcohol or nicotine abuse. Other possible causes of
unpleasant taste alterations arise from infection and
gastrointestinal reflux leading to the production of extraneous
substances (9).
In PD-1 andPD-L1-treated patients,moderate dysgeusia (grade
1 or 2) has also been observed in a minority of patients. One of the
various immune-related adverse events to be aware of is
pneumonitis (35). In the COVID-19 era, respiratory complaints,
dysgeusia andanosmia arepossible symptomsofSARS-CoV-2viral
infection, which can act as confounding factors in patients under
immunotherapy when identifying treatment toxicities (49).
In lung cancer patients undergoing treatment with immune
checkpoint inhibitors, the differential diagnosis between
pulmonary toxicity induced by drugs, infective pneumonitis
and tumor progression can be a major challenge (49).
Two randomized controlled trials (RCTs) investigated how
the incidence and severity of oral side effects of cancer therapy,
including dysgeusia, were affected by providing patients with
dietary counseling and educational tapes. However, overall,
dietary counseling as a single intervention only provided
limited benefit to some patients, and the manner of delivery of
the educational material to patients did not have a large
impact (9).
On the other hand, nutritional counseling combined with
taste and smell training and food enhancement may help the
treatment of taste alterations before further problems or
complications arise, particularly major weight loss and
malnutrition (20, 40, 41).
Umami is regarded as the signal for protein-rich food and
nutritious food, developing when meat and vegetables are cooked
or roasted, resulting in the release of glutamate in food. Glutamate
helps stimulate saliva production and appetite, reducing the cravingNovember 2021 | Volume 11 | Article 774081
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of umami and observed reductions in cancer patient meat
consumption could exist. Testing of glutamate could be a
predictor of a patient’s protein intake and its addition to a dish
may increase savory perception. This has potential implications for
supporting elderly cancer patients with healthier nutrition (40).
Despite conflicting results, studies reveal that systemic zinc
supplementation or zinc-based solutions may help prevent and
treat chemoradiotherapy-induced tissue damage, consequent
mucositis and taste disorders (50).
In line with these data, Yanase et al. retrospectively evaluated
the use of a 150 mg oral zinc solution 3 times per day before
meals in patients with NSCLC under weekly administration of
carboplatin and paclitaxel CT and concurrent chest RT. Grade ≥
2 radiation esophagitis development was significantly delayed by
oral zinc supplementation (HR, 0.397; 95% CI, 0.160–0.990;
p = 0.047) at the point of reached cumulative radiation dose of
40Gy (51, 52).
Despite the fact that mucositis and xerostomia are frequently
associated with taste alterations, we cannot necessarily assume
that by treating the first we will be able to improve the latter, as it
is reflected in various interventions improving oral mucositis,
but not TSAs.
Many unanswered questions remain to fully understand the
impact of lung cancer on taste and smell. Currently, standardized
methods are unavailable to accurately and consistently measure
taste and smell dysfunction across different clinical settings. This
makes it more difficult to analyze and interpret study results
given that self-reported taste and smell function is often not
objective. Without understanding taste and smell tissue
development, regeneration and degeneration at a cellular level,
it is not possible to identify and develop treatments to target the
sources of sensory dysfunction. For example, a consistent
method for regrowing human taste receptor cells or olfactory
neurons after injury or illness remains elusive, nor a method for
reconnecting those cells to the areas of the brain responsible for
taste and smell perception. Also, little progress has been made in
analyzing the fluids specific to each type of tissue (saliva for taste,
mucus for smell) for inflammation-related biomarkers or cellular
dysfunction (4).
So far, no guidelines for the treatment of taste disorders are
available, while there is a large need for trials to improve cancer
patient’s smell and taste with alternative interventions, as dietary
counseling alone seems to be of modest benefit to some
patients (9).Frontiers in Oncology | www.frontiersin.org 15CONCLUSIONS
Given the high frequency of TSAs and their impact on nutritional
status, treatment tolerance and QoL, normalizing and promoting
adequate adjustment to TSAs in lung cancer patients is relevant.
Potential taste and smell changes prior to lung cancer treatment
should be communicated clearly topatients, requiring clinicians tobe
appropriately trained and provided with validated evaluation
measures. Food enhancement through taste and smell training plus
personalized nutritional counseling combined with zinc
supplementation or use of oral zinc-based solutions seem to be
helpful in preventing and treating mucositis and taste disorders in
lung cancer patients under chemo-radiation treatment, although
adequately powered prospective RCTs are still lacking. Overall,
more work is needed to compensate for the lack of methods to
standardize smell and tastedysfunctionmeasurementacrossdifferent
clinical settings and the lack of understanding of the increased risk of
taste alterations associated with some patient and clinical
characteristics. Finally, it is critical to better understand, at the
cellular level, the development and regeneration of smell and taste
tissues. This could significantly help identify the sources of sensory
dysfunction and support the creation of targeted strategies for
treating taste and smell disorders in this cancer population.
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